Christopher Sweeney, MBBS, on Prostate Cancer: IMbassador250 Trial on Atezolizumab and Enzalutamide

Posted: Wednesday, May 6, 2020

Christopher Sweeney, MBBS, of the Dana-Farber Cancer Institute, discusses a phase III trial that tested whether combining enzalutamide with atezolizumab, vs enzalutamide alone, could improve outcomes in patients with metastatic castration-resistant prostate cancer.